Back to Search Start Over

18 F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging.

Authors :
Harada R
Hayakawa Y
Ezura M
Lerdsirisuk P
Du Y
Ishikawa Y
Iwata R
Shidahara M
Ishiki A
Kikuchi A
Arai H
Kudo Y
Yanai K
Furumoto S
Okamura N
Source :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Feb; Vol. 62 (2), pp. 253-258. Date of Electronic Publication: 2020 Jul 09.
Publication Year :
2021

Abstract

Reactive astrocytes play a key role in the pathogenesis of various neurodegenerative diseases. Monoamine oxidase-B (MAO-B) is one of the promising targets for the imaging of astrogliosis in the human brain. A novel selective and reversible MAO-B tracer, ( S )-(2-methylpyrid-5-yl)-6-[(3- <superscript>18</superscript> F-fluoro-2-hydroxy)propoxy]quinoline ( <superscript>18</superscript> F-SMBT-1), was successfully developed via lead optimization from the first-generation tau PET tracer <superscript>18</superscript> F-THK-5351. Methods: SMBT-1 was radiolabeled with <superscript>18</superscript> F using the corresponding precursor. The binding affinity of radiolabeled compounds to MAO-B was assessed using saturation and competitive binding assays. The binding selectivity of <superscript>18</superscript> F-SMBT-1 to MAO-B was evaluated by autoradiography of frozen human brain tissues. The pharmacokinetics and metabolism were assessed in normal mice after intravenous administration of <superscript>18</superscript> F-SMBT-1. A 14-d toxicity study after the intravenous administration of <superscript>18</superscript> F-SMBT-1 was performed using rats and mice. Results: In vitro binding assays demonstrated a high binding affinity of <superscript>18</superscript> F-SMBT-1 to MAO-B (dissociation constant, 3.7 nM). In contrast, it showed low binding affinity to MAO-A and protein aggregates such as amyloid-β and tau fibrils. Autoradiographic analysis showed higher amounts of <superscript>18</superscript> F-SMBT-1 binding in the Alzheimer disease brain sections than in the control brain sections. <superscript>18</superscript> F-SMBT-1 binding was completely displaced with the reversible MAO-B inhibitor lazabemide, demonstrating the high selectivity of <superscript>18</superscript> F-SMBT-1 for MAO-B. Furthermore, <superscript>18</superscript> F-SMBT-1 showed a high uptake by brain, rapid washout, and no radiolabeled metabolites in the brain of normal mice. <superscript>18</superscript> F-SMBT-1 showed no significant binding to various receptors, ion channels, or transporters, and no toxic effects related to its administration were observed in mice and rats. Conclusion: <superscript>18</superscript> F-SMBT-1 is a promising and selective MAO-B PET tracer candidate, which would be useful for quantitative monitoring of astrogliosis in the human brain.<br /> (© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)

Details

Language :
English
ISSN :
1535-5667
Volume :
62
Issue :
2
Database :
MEDLINE
Journal :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Publication Type :
Academic Journal
Accession number :
32646880
Full Text :
https://doi.org/10.2967/jnumed.120.244400